Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. - Wikidata - wikimedia - TriplyDB

Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.

Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.

http://www.wikidata.org/entity/Q33946560

about

Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer.Role of RUNX2 in Breast Carcinogenesis A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.Prostate cancer invasion and metastasis: insights from mining genomic data.Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion.NF-κB gene signature predicts prostate cancer progression.Gene targeting to the stroma of the prostate and bone.Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 in Vivo Biofunctionalization of electrospun PCL-based scaffolds with perlecan domain IV peptide to create a 3-D pharmacokinetic cancer model.Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis.Metastatic bone disease: role of transcription factors and future targets.Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone.Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteob Differential gene expression in ovarian carcinoma: identification of potential biomarkers Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression.MK591, a second generation leukotriene biosynthesis inhibitor, prevents invasion and induces apoptosis in the bone-invading C4-2B human prostate cancer cells: implications for the treatment of castration-resistant, bone-metastatic prostate cancer.Mechanisms of cancer cell metastasis to the bone: a multistep process.KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.Current and emerging therapies for bone metastatic castration-resistant prostate cancer.Expression of osteoprotegerin from a replicating adenovirus inhibits the progression of prostate cancer bone metastases in a murine model.Interaction among cells of bone, immune system, and solid tumors leads to bone metastases.Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies.Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis.The Impact of Immune System in Regulating Bone Metastasis Formation by Osteotropic Tumors.Distinct Osteomimetic Response of Androgen-Dependent and Independent Human Prostate Cancer Cells to Mechanical Action of Fluid Flow: Prometastatic Implications.p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells.Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer.In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth.Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells.Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models.p62/SQSTM1 is required for cell survival of apoptosis-resistant bone metastatic prostate cancer cell lines.The current status of prophylactic femoral intramedullary nailing for metastatic cancer Crocus sativus stigma extract and its major constituent crocin possess significant antiproliferative properties against human prostate cancer.Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells.Differences in the pattern and regulation of mineral deposition in human cell lines of osteogenic and non-osteogenic origin.Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells.

P2860

Q27331671-4C601135-194B-4C28-866A-ACB10103DB1A Q28084968-36DBA7D6-1F04-4F65-9662-30451814736C Q30504566-F433DC2B-D316-406E-92B4-15ACF41BC1A9 Q30656758-B4063635-469E-4381-9B21-8017E86DAC89 Q33409529-723A7456-AA76-4501-AB97-1D4F0015BCD4 Q33624908-CB88A9A2-5BFC-47E1-865E-6733E02A3D6B Q33699188-E94C28E2-E013-414B-9DA2-3A2E865695D3 Q33767832-957E0201-A51B-41E1-B441-98372F204922 Q33872737-55717EAE-2C3F-4D23-9280-39A14C1496A2 Q34107357-C63E82D1-50A1-4D35-B968-C2C89C1E85F4 Q34217531-9D76371C-A37D-4360-ACD9-F30C4942C329 Q34664057-A16FFBDE-825F-4A3A-B3D5-2A013AE73EF5 Q34971654-52CBE2D4-FB29-482C-85F4-01407F5C22E7 Q35103006-A2E52115-61E1-46C1-8263-EDD5EE08EDA5 Q35185387-AABC2787-DDF8-4416-BF30-371656AC713A Q35431448-A02E0338-5B19-41D1-9CDD-A25F7CC07FEA Q35673417-540CF6C1-8C9D-43B1-8386-9C0717A767F0 Q35856215-B69DA363-0B6B-43DE-AEA4-4AB1E5BB7D45 Q36062138-C46361FE-021E-4AA5-80F6-DD063649358D Q36278275-54CBB056-F1F3-47A0-B424-143DDB8E3935 Q36358303-53944502-8519-49B5-8BAF-E1B73A7849F7 Q36644377-6AAF2A79-CF43-4472-AF39-C778F886C8A0 Q36848283-792C4986-3953-4683-8074-FA6E7C2BC4B9 Q37558837-D7B293D5-626E-4FEA-9E65-D297169FAB54 Q38340672-0FD5B818-29D2-4B47-8A61-0E6E86395E45 Q38524842-F01522E5-5110-43C2-968A-81EB5E0E8520 Q38733024-3777CA87-696E-4755-AB3C-4A8FB4AAB869 Q38791188-E7D21E1A-8DBD-42AE-AD51-684F0728F82F Q38819069-84B5E159-64BC-4DAC-B25C-4842A669DC4C Q38971331-B7398CFB-FC26-4D47-A793-EADB68F2A38D Q39001159-6C5D6312-A883-4737-B18E-CE1C45E3B6C7 Q39006052-A39D8EA2-17A4-4CA7-BDE4-72FB64BF245E Q39079576-097B66EB-AD7B-4ACD-890C-ECE1F590EDF8 Q39095826-A0C1540D-B045-45D2-BB7F-11DF07E656B3 Q39116476-E20AFAA2-F080-4966-9330-00D775F2A682 Q39258781-F90FE107-BF2E-4EC0-A8C8-A2FA6E6D00F7 Q39436234-1668676E-40C2-4B66-B268-B3EC6D40FC8D Q39516408-C900FC30-4542-4006-BBCD-CEE82A00C215 Q39568883-E571C35A-5CA2-4658-AC79-94A3CB4EE4A1 Q39585352-2F8FE32E-1B34-4939-A5CB-8C21223944C1

P2860

Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.

http://www.wikidata.org/entity/Q33946560

description

2001 nî lūn-bûn

@nan

2001 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.

@ast

Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.

@en

type

label

Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.

@ast

Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.

@en

prefLabel

Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.

@ast

Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.

@en

P1433

Q33946560-E0C47567-7271-4F28-B57F-464BD74B002F

P1476

Q33946560-C49E8851-3541-46C0-ACBD-E2C861032565

P2093

Q33946560-22F6CF4C-D2F2-475E-8226-FB4490E1D37D

Q33946560-4DEED172-6E4E-4944-86B7-7723ED62C268

Q33946560-6B19A9D6-F764-42E7-A86A-8EFC2E76236E

Q33946560-720F3C5F-5419-4928-91A7-B1D12CCCE6BC

Q33946560-9C7CE8A0-DE23-40B7-BF97-E12FD118F764

Q33946560-A79988EE-305B-4776-8C56-072A172FEEED

Q33946560-AACE8498-D7F2-4FB7-8166-FD7CC4CB527B

Q33946560-CAFA849E-A7D3-4BA5-8186-D90609910754

P2860

Q33946560-11BFF9D5-2609-4818-AF23-7438778C7E29

Q33946560-1D47C134-4B90-4BA0-B97C-5D40DF1B7885

Q33946560-24100E0B-8DB4-4E80-9ED0-C3D182C6D1AC

Q33946560-2734F882-53CA-43F4-8FBF-F1FD4B8AEC44

Q33946560-327C9C1A-546B-46C7-99BD-40652015A308

Q33946560-3B8693A4-0244-485E-8F34-E6E47EFDADC7

Q33946560-3D87AFFE-5FFF-4F7F-9683-8C1758E9A7F0

Q33946560-68713E84-67E5-4738-BCE5-BA38E7C2397D

Q33946560-6AEFDC5E-BB5A-4350-AD76-47CFFBF54EED

Q33946560-6BF60531-9FBC-4411-B702-F34E0956B0A9

P304

Q33946560-4A0FA993-7290-4354-B115-633810D85726

P31

Q33946560-6D4DAC68-E58E-4DFF-A760-492529B97AC2

P356

Q33946560-CD4ABDDD-D0CA-42E5-AD98-8C303225B64F

P433

Q33946560-CC10AE68-3976-4353-B2A5-4216EB1DA996

P478

Q33946560-8EF27907-C7BC-4FDA-B3A5-AD40A24C9AE3

P577

Q33946560-DAA5E47A-F83D-4ABC-8DB1-A08A9C218AAF

P5875

Q33946560-AE8061F1-E894-42BD-9E76-93B98BEF47C5

P698

Q33946560-A9F8D3E5-18B5-40BA-B4DD-FA4AF01DE92F

P356

P1433

P1476

Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.

@en

P2093

Dai J

http://www.w3.org/2001/XMLSchema#string

Keller ET

http://www.w3.org/2001/XMLSchema#string

Lin DL

http://www.w3.org/2001/XMLSchema#string

Morris MD

http://www.w3.org/2001/XMLSchema#string

Patel AH

http://www.w3.org/2001/XMLSchema#string

Rohn E

http://www.w3.org/2001/XMLSchema#string

Tarnowski CP

http://www.w3.org/2001/XMLSchema#string

Zhang J

http://www.w3.org/2001/XMLSchema#string

P2860

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis

Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation

Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation

Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts

The distribution of secondary growths in cancer of the breast. 1889

Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment.

Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.

The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

Application of vibrational spectroscopy to the study of mineralized tissues (review).

P304

212-221

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PROS.1065

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2001-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11986982

http://www.w3.org/2001/XMLSchema#string

P698

11351351

http://www.w3.org/2001/XMLSchema#string